Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | SQLE | Q14534 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | ICMT | O60725 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9238573 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL255003 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL16485660 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL1586840 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL2250076 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL158315 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11844736 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11844741 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL442001 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL12293765 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150133431-A1 | GGA DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133431-A1 | GGA DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133431-A1 | GGA DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| WO-2014163643-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20130245126-A1 | GERANYLGERANYLACETONE FORMULATIONS AND RETINAL DELIVERY THEREOF | COYOTE PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245126-A1 | GERANYLGERANYLACETONE FORMULATIONS AND RETINAL DELIVERY THEREOF | COYOTE PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013130242-A1 | GERANYLGERANYLACETONE FORMULATIONS | COYOTE PHARMACEUTICALS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130654-A1 | GGA AND GGA DERIVATIVES, COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-2611765-A2 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Coyote Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20120172453-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | COYOTE PHARMACEUTICALS, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172453-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | COYOTE PHARMACEUTICALS, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172453-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | COYOTE PHARMACEUTICALS, INC. | 2012-07-05 | — | — | US | disclosed |
| WO-2012031028-A2 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | COYOTE PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031028-A2 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | COYOTE PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133431-A1 | GGA DERIVATIVES | PGGT1B, RABGGTB, GGPS1 | KMT2A 3804/4885MAPT 2889/4885MEN1 3141/4885 |
| US-20120172453-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES | API5, GAP43, GRN | KMT2A 4842/4885MAPT 325/4885MEN1 4487/4885 |
| US-20130245126-A1 | GERANYLGERANYLACETONE FORMULATIONS AND RETINAL DELIVERY THEREOF | ALDH1A2, GGPS1, FNTA | KMT2A 4758/4885MAPT 229/4885MEN1 2854/4885 |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | KMT2A 3588/4885MAPT 893/4885MEN1 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.